Keeping Up With Biosimilars

(B6) Biosimilar Operational Readiness: Managed Care Stakeholder Preparation for Market Expansion

Thursday, March 23, 2023

4:30 PM – 5:45 PM

Location: B1

ACPE UAN:0233-0000-23-019-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Molly Borchardt, PharmD

Director, Specialty Pharmacy and Innovation
Blue Cross Blue Shield of North Carolina
Durham, NC
KL

Kim N. Le, PharmD

Vice President, National Clinical Pharmacy Services
Kaiser Permanente
Downey, CA
Gary Rice, RPh MS MBA CSP (he/him/his)

Senior Advisor
MedImpact Healthcare System, Inc
Fenton, MI

Moderator(s)

Cate Lockhart, MS, PharmD, PhD

Executive Director
Biologics and Biosimilars Collective Intelligence Consortium
Alexandria, VA

With the emergence of biologics in the chronic inflammatory diseases space, all eyes are focused on the current and upcoming biosimilar pipeline. Many prominently used biologics are scheduled to lose patent protection in 2023, paving the way for a new wave of biosimilars to flood the marketplace.

It is crucial for managed care and other health professionals to monitor this unprecedented influx of biosimilars and its potential impact on pharmacy operations, patient care, and related cost savings.

This panel session will provide various managed care pharmacy perspectives on preparing for the biosimilar market expansion, including potential challenges and solutions.

Learning Objectives::

At the completion of this activity, participants should be able to:

Summarize the benefits and challenges of the potential biosimilar marketing expansion in 2023.
Identify possible managed care pharmacy strategies for managing biosimilar marketing expansion including the impacts on pharmacy operations and providers.
Describe strategies for improving education and adoption of biosimilars among key stakeholders including providers and pharmacy staff.